LB Pharmaceuticals Inc Common Stock
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.67 | $0 | -$23M |
| 2025 Q4 | -0.45 | $0 | -$18M |
| 2025 Q3 | -0.14 | $0 | -$3M |
| 2025 Q2 | -20.21 | $0 | -$7M |
| 2025 Q1 | -20.21 | $0 | -$8M |
| 2024 Q3 | -0.63 | $0 | -$22M |
| 2024 Q2 |
| -7.82 |
| $0 |
| -$16M |
| 2024 Q1 | -4.56 | $0 | -$10M |